A new addition to my portfolio and the Best stocks list: Medicines Company is a global biopharmaceutical company, with have four marketed products, Angiomax® (bivalirudin), Recothrom® Thrombin, topical (Recombinant), Cleviprex ® (clevidipine butyrate). They also have a pipeline of acute and intensive care hospital products in development, including four late-stage development product candidates, cangrelor, oritavancin, MDCO-157 and IONSYS TM (fentanyl iontophoretic transdermal system), and early stage development product candidates, MDCO-216 and ALN-PCS02 and ALN-PCSsc of our ALN-PCS program.
The vast majority of their sales comes from Angiomax, however their other products are growing at a faster pace, with 4 more launching in the next 12-24 months. In the latest quarterly results, net revenues grew by 27% to 174.3 million USD, and adjusted net income 100% to 29.3 million USD. The growth is expected around 30% CAGR, which is quite in line with a 32 forward P/E. The patent for Angiomax will expire in 2019, however it's growth and the pipeline of new drugs should be more than sufficient for the future.
The vast majority of their sales comes from Angiomax, however their other products are growing at a faster pace, with 4 more launching in the next 12-24 months. In the latest quarterly results, net revenues grew by 27% to 174.3 million USD, and adjusted net income 100% to 29.3 million USD. The growth is expected around 30% CAGR, which is quite in line with a 32 forward P/E. The patent for Angiomax will expire in 2019, however it's growth and the pipeline of new drugs should be more than sufficient for the future.
RSS Feed